Phospholipase C News and Research

RSS

Immune system misinterprets threats and attacks body's own cells and tissue

Many chronic diseases are the result of the body's immune system mistakenly perceiving that the body is under attack from foreign bodies. A counterattack is then launched - an inflammatory response meant to vanquish the intruder. In reality, the immune system has misinterpreted the threat and is actually attacking the body's own cells and tissue.

24 Mar 2011

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers.

17 Sep 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

Blood biomarker underscores role of inflammation in vascular disease

UC Davis researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans.

21 May 2010

Elevated levels of Lp-PLA2 associated with increased risk of coronary heart disease

A meta-analysis of approximately 80,000 individuals from 32 prospective studies was published in The Lancet on May 1, 2010. The data shows that elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated with an increased risk of coronary heart disease similar in magnitude to that with non-HDL cholesterol or systolic blood pressure.

20 May 2010

Tocotrienol form of vitamin E prevents neural cell death and rescues the brain after stroke injury

Blocking the function of an enzyme in the brain with a specific kind of vitamin E can prevent nerve cells from dying after a stroke, new research suggests.

12 Jan 2010

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

Discovery of novel tumor suppressor

4 Aug 2009

Discovery of novel tumor suppressor

La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of the blood.

3 Aug 2009

Research shows how resveratrol works as an effective therapy for life-threatening inflammation

Scientists from Scotland and Singapore have unraveled a mystery that has perplexed scientists since red wine was first discovered to have health benefits: how does resveratrol control inflammation?

31 Jul 2009

Discovery of new potential therapeutic target for Barth Syndrome

Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).

2 Mar 2009

New inhibitors could be new class of cancer drugs

A team of Vanderbilt University Medical Center investigators has developed a group of chemical compounds that could represent a new class of drugs for treating cancer.

3 Feb 2009

Theraputic target for prostate cancer

The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.

14 Jan 2009

New genetic markers for ulcerative colitis could lead to treatment

An international consortium of researchers, including major contribution from a team led by Dr. John D. Rioux, a professor of medicine at the Université de Montréal and the Montreal Heart Institute, has identified genetic markers associated with risk for ulcerative colitis.

8 Jan 2009

Discovery of new genetic markers for ulcerative colitis

An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.

5 Jan 2009

Two common biomarkers help predict stroke risk

Two common biomarkers have now been shown to improve the ability to predict who will suffer from a stroke.

18 Dec 2008

Exciting cancer discovery

Metastasis is the ability of cancer cells to spread from a primary site, to form tumours at distant sites.

14 Dec 2008

Presence of gum disease may help dentists and physicians identify risk of cardiovascular disease

Individuals reporting a history of periodontal disease were more likely to have increased levels of inflammation, a risk factor for heart disease, compared to those who reported no history of periodontal disease, according to an American Journal of Cardiology report available online today.

25 Nov 2008

Fatty acids may be the culprit in Alzheimer's

According to new research from the U.S. controlling the level of a fatty acid in the brain could help treat Alzheimer's disease (AD).

21 Oct 2008

Phospholipase C News and Research

Immune system misinterprets threats and attacks body's own cells and tissue

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

Blood biomarker underscores role of inflammation in vascular disease

Elevated levels of Lp-PLA2 associated with increased risk of coronary heart disease

Tocotrienol form of vitamin E prevents neural cell death and rescues the brain after stroke injury

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Discovery of novel tumor suppressor

Discovery of novel tumor suppressor

Research shows how resveratrol works as an effective therapy for life-threatening inflammation

Discovery of new potential therapeutic target for Barth Syndrome

New inhibitors could be new class of cancer drugs

Theraputic target for prostate cancer

New genetic markers for ulcerative colitis could lead to treatment

Discovery of new genetic markers for ulcerative colitis

Two common biomarkers help predict stroke risk

Exciting cancer discovery

Presence of gum disease may help dentists and physicians identify risk of cardiovascular disease

Fatty acids may be the culprit in Alzheimer's

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News